Free Trial

ASR Vermogensbeheer N.V. Invests $465,000 in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Neurocrine Biosciences logo with Medical background

Key Points

  • ASR Vermogensbeheer N.V. has invested approximately $465,000 in Neurocrine Biosciences, acquiring 4,208 shares of the company's stock.
  • Institutional investors hold about 92.59% of Neurocrine's stock, with several firms like Dodge & Cox and UBS AM significantly increasing their stakes in the 4th quarter.
  • Neurocrine's stock has seen a recent price target increase, with UBS Group raising it from $152.00 to $174.00 and maintaining a "buy" rating.
  • Need Better Tools to Track Neurocrine Biosciences? Try 5 Weeks of MarketBeat All Access for $5. Start Portfolio Tracking Now.

ASR Vermogensbeheer N.V. bought a new position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 4,208 shares of the company's stock, valued at approximately $465,000.

Several other hedge funds and other institutional investors also recently made changes to their positions in the business. Dodge & Cox boosted its stake in shares of Neurocrine Biosciences by 134.2% during the 4th quarter. Dodge & Cox now owns 3,016,425 shares of the company's stock worth $411,742,000 after acquiring an additional 1,728,605 shares during the period. AQR Capital Management LLC boosted its stake in Neurocrine Biosciences by 2.9% in the 4th quarter. AQR Capital Management LLC now owns 1,896,891 shares of the company's stock valued at $258,926,000 after purchasing an additional 53,610 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in Neurocrine Biosciences by 19.7% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,070,096 shares of the company's stock valued at $146,068,000 after purchasing an additional 175,879 shares during the period. Northern Trust Corp boosted its stake in Neurocrine Biosciences by 27.3% in the 4th quarter. Northern Trust Corp now owns 981,939 shares of the company's stock valued at $134,035,000 after purchasing an additional 210,315 shares during the period. Finally, Invesco Ltd. boosted its stake in Neurocrine Biosciences by 8.6% in the 4th quarter. Invesco Ltd. now owns 949,512 shares of the company's stock valued at $129,608,000 after purchasing an additional 74,847 shares during the period. 92.59% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other Neurocrine Biosciences news, insider Ingrid Delaet sold 457 shares of the company's stock in a transaction dated Thursday, July 10th. The stock was sold at an average price of $135.00, for a total value of $61,695.00. Following the completion of the transaction, the insider owned 4,730 shares of the company's stock, valued at $638,550. This represents a 8.81% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Jude Onyia sold 59,819 shares of the company's stock in a transaction dated Wednesday, July 9th. The stock was sold at an average price of $130.46, for a total value of $7,803,986.74. Following the completion of the transaction, the insider directly owned 18,289 shares of the company's stock, valued at approximately $2,385,982.94. The trade was a 76.58% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 90,251 shares of company stock valued at $11,672,602 in the last 90 days. Corporate insiders own 4.80% of the company's stock.

Wall Street Analyst Weigh In

Several analysts recently issued reports on NBIX shares. UBS Group boosted their price target on Neurocrine Biosciences from $152.00 to $174.00 and gave the company a "buy" rating in a research note on Wednesday, July 9th. Evercore ISI reduced their price target on Neurocrine Biosciences from $190.00 to $185.00 and set an "outperform" rating for the company in a research note on Thursday, April 24th. Wall Street Zen upgraded Neurocrine Biosciences from a "hold" rating to a "strong-buy" rating in a research note on Saturday, August 2nd. Canaccord Genuity Group boosted their price target on Neurocrine Biosciences from $158.00 to $160.00 and gave the company a "buy" rating in a research note on Tuesday, May 6th. Finally, Wedbush upped their target price on Neurocrine Biosciences from $137.00 to $141.00 and gave the company an "outperform" rating in a research report on Thursday, July 31st. Three equities research analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $160.90.

Check Out Our Latest Stock Report on NBIX

Neurocrine Biosciences Stock Performance

Neurocrine Biosciences stock opened at $125.01 on Friday. Neurocrine Biosciences, Inc. has a 52 week low of $84.23 and a 52 week high of $154.87. The stock has a market capitalization of $12.40 billion, a P/E ratio of 36.99, a price-to-earnings-growth ratio of 0.90 and a beta of 0.25. The stock has a fifty day moving average of $128.72 and a 200-day moving average of $120.29.

Neurocrine Biosciences (NASDAQ:NBIX - Get Free Report) last issued its earnings results on Wednesday, July 30th. The company reported $1.06 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.98 by $0.08. Neurocrine Biosciences had a return on equity of 13.22% and a net margin of 13.88%. The business had revenue of $687.50 million during the quarter, compared to analysts' expectations of $653.09 million. During the same quarter in the prior year, the firm earned $1.63 EPS. The business's revenue for the quarter was up 16.5% compared to the same quarter last year. On average, research analysts forecast that Neurocrine Biosciences, Inc. will post 4.28 earnings per share for the current year.

About Neurocrine Biosciences

(Free Report)

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.

See Also

Want to see what other hedge funds are holding NBIX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report).

Institutional Ownership by Quarter for Neurocrine Biosciences (NASDAQ:NBIX)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Neurocrine Biosciences Right Now?

Before you consider Neurocrine Biosciences, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Neurocrine Biosciences wasn't on the list.

While Neurocrine Biosciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 Growth Stocks That Could Pop Before Summer Ends
3 Buy-the-Dip Stocks Poised to Rebound Soon
Quantum Boom: 3 Strong Picks with Lower Risk

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines